Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thioepipstatin for prevention of chemotherapy-related neutropenia in nasopharyngeal carcinoma
ChiCTR1900025453Phase 4Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of thioepipstatin in chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Febrile neutropenia incidence rate during chemotherapy. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
thioepipstatin
03
Conditions
chemotherapy-induced neutropenia (CIN)febrile neutropenia (FN)
Beyond the preview
Go deeper on ChiCTR1900025453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025453.